Consensus Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
15.41 ^USD	+1.03%		+10.05%	0.00%

May. 14	Kyverna Therapeutics Q1 Loss Narrows	MT
Apr. 25	Nasdaq's revenue beats on strong demand for fintech products	RE

Evolution of the average Target Price on Kyverna Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f1afbe3adc5adca9e9e8a554c.-N11gz8S8aydb3GskvSaKhdFh8OBeQ96XlobYWiEQ44.j4QQ6X5WiMjCQjLE9cX4YWYxqo3CFmwTCAp1UBrnMcKUkzm1fnGu_602PA~390b059ceb7520bfcb62d03e0e0e4030

Analyst Recommendations on Kyverna Therapeutics, Inc.

JPMorgan Initiates Kyverna Therapeutics With Overweight Rating	Mar. 04	MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating	Mar. 04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.42 USD

Average target price

42.75 USD

Spread / Average Target

+177.24%

High Price Target

48 USD

Spread / Highest target

+211.28%

Low Price Target

39 USD

Spread / Lowest Target

+152.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kyverna Therapeutics, Inc.

Morgan Stanley
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar